# CNM-Au8 (cnm-au8) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cnm-au8

> CNM-Au8 (cnm-au8), sponsored by Clene Inc. (CLNN): 6 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | CNM-Au8 (cnm-au8) |
| Codes |  |
| Sponsor | Clene Inc. (CLNN) https://sec-api.dev/companies/clnn/catalysts |
| Indications | [amyotrophic lateral sclerosis](https://sec-api.dev/indications/amyotrophic-lateral-sclerosis) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Oct 2022: topline data readout

- Status: completed, mixed. Date confidence: month.
- First seen 2025-03-24, last confirmed 2025-03-24.
- SEC Form 10-K (accession 0001437749-25-008956): "In October 2022, we announced topline results for CNM-Au8: the primary endpoint of rate of change in ALSFRS-R adjusted for mortality was not statistically significant at 24 weeks (2% slowing, 95% CI: -20% to +19%)." https://www.sec.gov/Archives/edgar/data/1822791/000143774925008956/clnn20241231_10k.htm

### Q4 2025: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2025-03-24, last confirmed 2025-08-14.
- Press release filed with the SEC (EX-99) (accession 0001437749-25-026690): "The Company expects to submit a New Drug Application in the fourth quarter of 2025 for potential accelerated approval of CNM-Au8® in ALS" https://www.sec.gov/Archives/edgar/data/1822791/000143774925026690/ex_829965.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-008869): "Clene planning to submit a New Drug Application (NDA) in the second half of 2025 for potential Accelerated Approval of CNM-Au8® in ALS" https://www.sec.gov/Archives/edgar/data/1822791/000143774925008869/ex_727055.htm

### Q1 2026: PDUFA date

- Status: scheduled. Date confidence: quarter.
- First seen 2026-01-13, last confirmed 2026-01-13.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-001196): "The exercise price of each Series A Warrant will increase to $7.00 per share if either: (a) the warrant is exercised prior to the Company's public announcement of the FDA's posted PDUFA action date for the CNM-Au8 NDA (the "PDUFA Date Announcement"), which is expected to occur in the first quarter of 2026; or (b) the volume-weighted average price of the Company's common stock equals or exceeds $10.00 on the measurement date associated with the PDUFA Date Announcement." https://www.sec.gov/Archives/edgar/data/1822791/000143774926001196/ex_905866.htm

### June 16, 2026: NDA/BLA acceptance

- Status: completed. Date confidence: exact.
- First seen 2026-09-16, last confirmed 2026-09-16.
- SEC prospectus (424B) (accession 0001437749-26-030521): "The Tranche A Warrants were exercisable immediately and will expire on the earlier of (i) sixty (60) days following the date of our public announcement that the filing of a New Drug Application ("NDA") for CNM-Au8 has been accepted by the U.S. Food and Drug Administration ("FDA"), or (ii) June 16, 2026." https://www.sec.gov/Archives/edgar/data/1822791/000143774926030521/clnn20260911_424b5.htm

### Q4 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2026-05-14, last confirmed 2026-08-14.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-027837): "Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026" https://www.sec.gov/Archives/edgar/data/1822791/000143774926027837/ex_967804.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-016881): "After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8® under the accelerated approval pathway in the third quarter of 2026" https://www.sec.gov/Archives/edgar/data/1822791/000143774926016881/ex_908797.htm

### October 19, 2026: NDA/BLA submission

- Status: completed. Date confidence: exact. Indication: amyotrophic lateral sclerosis.
- First seen 2026-10-19, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-032882): "SALT LAKE CITY, October 19, 2026 — Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on revolutionizing the treatment of neurodegenerative diseases, announced that it has submitted a New Drug Application (NDA) earlier in October to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of CNM-Au8® for the treatment of amyotrophic lateral sclerosis (ALS)." https://www.sec.gov/Archives/edgar/data/1822791/000143774926032882/ex_1027473.htm
- SEC Form 10-Q (accession 0001437749-26-034776): "In October 2026, we submitted a new drug application ("NDA") to the U.S. Food and Drug Administration ("FDA") seeking accelerated approval of CNM-Au8® for the treatment of ALS." https://www.sec.gov/Archives/edgar/data/1822791/000143774926034776/clnn20260930_10q.htm

## Same indication

- [INS1202](https://sec-api.dev/pdufa/ins1202) (INSM)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cnm-au8.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "CNM-Au8 (cnm-au8) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cnm-au8

```bibtex
@misc{secapidev_pdufa_cnm_au8_20261116,
  title        = {CNM-Au8 (cnm-au8) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cnm-au8}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cnm_au8_20261116","title":"CNM-Au8 (cnm-au8) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cnm-au8","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
